Some diseases are notoriously hard targets for new pharmaceutical
development, and Alzheimer's may well be one of the worst. There are
very few drugs on the market for the disease (Forest Labs' (FRX) Namenda and Pfizer's (PFE) Aricept are the two most prominent), but Johnson & Johnson (JNJ), Pfizer, and Elan (ELN) hoped to defy the odds and bring a new Alzheimer's drug to market - bapineuzumab.
Unfortunately, Pfizer's news announcement Monday after the close largely brings that hope to an end.
Read more here:
A Disappointing, But Not Altogether Surprising, Failure For JNJ And Pfizer
No comments:
Post a Comment